Bio-Gate AG Adjusts 2026 Financial Forecasts Amid Customer Changes

Bio-Gate AG, a notable name in antimicrobial technologies, has revised its financial outlook for the fiscal year 2026. Two of its major clients, operating in human and animal care products, are undergoing portfolio and structural transformations. Consequently, this will result in a significant reduction in order volumes, impacting its Derma-Cosmetics and Wound Care segments. The company's implant coatings business remains unaffected.

The adjusted forecast predicts a consolidated revenue between 6.0 and 6.9 million euros, down from an initial estimate of 6.9 to 7.9 million euros. The EBITDA is now anticipated to be between minus 0.9 and minus 1.1 million euros, close to the previous year's minus 0.9 million euros. EBIT is expected to range from minus 1.1 to minus 1.5 million euros.

For 2027, Bio-Gate AG expects a return to growth, with new product launches planned for both major clients.